Guides
What did the 72-week trial comparing tirzepatide and semaglutide show?
Short answer
In SURMOUNT-5, investigators randomly assigned 751 adults to two treatment groups. At 72 weeks the estimated mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide. The gap between the rounded averages was 6.5 percentage points. Each percentage uses starting weight as its reference.1
Why compare groups within the same trial?
Two separate trials can give different numbers because they recruited different people or measured weight at different times. Here the groups followed the same study protocol for the same duration. Random assignment makes the groups more comparable on average.2
What does open-label mean here?
Participants and treating staff knew which medicine had been assigned. Change in body weight was among the outcomes measured. The study cannot isolate how much expectations or changes in behaviour may have contributed to an observed result. Eli Lilly funded the trial.1
Who do the findings describe?
Participants were adults with obesity or with overweight and at least one weight-related condition. People with diabetes were excluded. The comparison followed groups up to week 72. For a personal decision, discuss possible side effects, other conditions and the treatment outcome that matters to you with your clinician.2
Primary sources
- Aronne et al. (2025), original SURMOUNT-5 publication, DOI 10.1056/NEJMoa2416394
- ClinicalTrials.gov, SURMOUNT-5 trial design and eligibility
Cite this page
Fastzuleicht · Editorial team. What did the 72-week trial comparing tirzepatide and semaglutide show? (18 November 2026). https://fastzuleicht.de/guides/tirzepatide-semaglutide-head-to-head-trial/